MX2022008628A - Uso de ketamina en el tratamiento de caquexia. - Google Patents

Uso de ketamina en el tratamiento de caquexia.

Info

Publication number
MX2022008628A
MX2022008628A MX2022008628A MX2022008628A MX2022008628A MX 2022008628 A MX2022008628 A MX 2022008628A MX 2022008628 A MX2022008628 A MX 2022008628A MX 2022008628 A MX2022008628 A MX 2022008628A MX 2022008628 A MX2022008628 A MX 2022008628A
Authority
MX
Mexico
Prior art keywords
ketamine
cachexia
treatment
elevate
administered
Prior art date
Application number
MX2022008628A
Other languages
English (en)
Inventor
James Chyan- Ji Wang
Original Assignee
Astromedical Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astromedical Biotechnology Ltd filed Critical Astromedical Biotechnology Ltd
Publication of MX2022008628A publication Critical patent/MX2022008628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Se describe en la presente el uso de ketamina en el tratamiento de caquexia, en donde la ketamina es administrada a un sujeto quién es tratado con 5-FU y la cantidad de dosis de ketamina es aproximadamente 60% para 5-FU. Específicamente, se usa la ketamina en la presente invención para elevar la tasa de sobrevivencia y mejorar la reducción de peso causada por la caquexia.
MX2022008628A 2020-01-13 2020-11-19 Uso de ketamina en el tratamiento de caquexia. MX2022008628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062960255P 2020-01-13 2020-01-13
PCT/US2020/061187 WO2021145952A1 (en) 2020-01-13 2020-11-19 Use of ketamine in the treatment of cachexia

Publications (1)

Publication Number Publication Date
MX2022008628A true MX2022008628A (es) 2022-09-26

Family

ID=76760670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008628A MX2022008628A (es) 2020-01-13 2020-11-19 Uso de ketamina en el tratamiento de caquexia.

Country Status (13)

Country Link
US (1) US11400060B2 (es)
EP (1) EP4090326A4 (es)
JP (1) JP7353687B2 (es)
KR (1) KR102530724B1 (es)
CN (1) CN115279354B (es)
AU (1) AU2020422620A1 (es)
BR (1) BR112022013755A2 (es)
CA (1) CA3167710C (es)
IL (1) IL294709B2 (es)
MX (1) MX2022008628A (es)
TW (1) TWI786498B (es)
WO (1) WO2021145952A1 (es)
ZA (1) ZA202208468B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
EP1395289B1 (en) * 2001-06-07 2010-12-15 Christine Dr. Sang Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
JP5627452B2 (ja) * 2007-04-24 2014-11-19 アカシア ファーマ リミテッドＡｃａｃｉａ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 筋肉減少の治療に使用される薬剤の組合せ
CA2721927C (en) * 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20160166683A1 (en) * 2009-12-15 2016-06-16 lseu da Silva NUNES Adjuvant immunotherapy for the treatment cancer, of clinical manifestations associated with the diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, secundary cachexia, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments
WO2019169165A1 (en) * 2018-02-28 2019-09-06 Novocine Therapeutics, Llc Ketamine and ketamine-related compounds for the treatment of neurological disorders
US10975146B2 (en) * 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Also Published As

Publication number Publication date
CN115279354A (zh) 2022-11-01
IL294709A (en) 2022-09-01
US11400060B2 (en) 2022-08-02
JP7353687B2 (ja) 2023-10-02
IL294709B1 (en) 2023-03-01
CA3167710A1 (en) 2021-07-22
BR112022013755A2 (pt) 2022-10-11
CA3167710C (en) 2023-03-28
AU2020422620A1 (en) 2022-08-25
WO2021145952A1 (en) 2021-07-22
KR102530724B1 (ko) 2023-05-09
TW202135788A (zh) 2021-10-01
JP2023500172A (ja) 2023-01-04
EP4090326A4 (en) 2024-01-17
TWI786498B (zh) 2022-12-11
IL294709B2 (en) 2023-07-01
EP4090326A1 (en) 2022-11-23
CN115279354B (zh) 2024-07-19
US20210212965A1 (en) 2021-07-15
ZA202208468B (en) 2023-04-26
KR20220127852A (ko) 2022-09-20

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2010005441A (es) Metodo para aumentar la eficacia terapeutica de los curcuminoides y analogos.
MX2022010852A (es) Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
MX2024005453A (es) Composiciones y tratamientos con nirogacestat.
HUP0301828A2 (hu) Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására
MX2022008628A (es) Uso de ketamina en el tratamiento de caquexia.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2023008447A (es) Composiciones y metodos para prevenir, mejorar o reducir enfermedades inducidas por radiacion.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
NZ707246A (en) Uses of Bremelanotide in Therapy for Female Sexual Dysfunction
ATE293983T1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
Wang et al. Metronomic Effect of Norcantharidin Hydrogel in Nude Mice with Human Hepatocellular Carcinomas Xenografts
WO2023028519A3 (en) Methods of treating substance use disorder
Teleki et al. Effects of quercetin on the state of antioxidant system disbalance with chronic obstructive pulmonary disease with chronic pancreatitis
MX2023011173A (es) Nueva aplicacion de una composicion inmunogenica o de vacuna contra la enfermedad por coronavirus 2019.
MX2023002650A (es) Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.
CN109418485A (zh) 一种养生茶